Skip to main content

Table 2 Primary outcome total plaque volume percent change and absolute change from baseline to month 6 and exploratory plaque variables

From: Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndrome

Variable

L-C

Mean change

(95%CI)

L-C

p value

Placebo

Mean Change

(95%CI)

Placebo p value

Between-Arm Diff. Mean (95%CI)

Between-Arm Diff

p value

Percent change

      

 TPV (%)

− 2.4 (− 5.3 to 0.6)

0.12

− 1.2 (− 4.0 to 1.8)

0.44

− 1.2 (− 5.3 to 3.0)

0.56

 Stenosis (%)

4.6 (− 0.7 to 10.3)

0.09

− 4.3 (− 9.0 to 0.7)

0.09

9.3 (1.6 to 17.6)

0.02*

 CIMT (%)

0.70 (− 1.8 to 3.3)

0.58

0.40 (− 2.0 to 2.9)

0.75

0.30 (− 3.2 to 3.9)

0.86

 MPH (%)

0.1 (− 3.5 to 3.9)

0.95

2.8 (− 0.9 to 6.6)

0.14

− 2.6 (− 7.6 to 2.6)

0.32

 TPA (%)

− 1.7 (− 6.7 to 3.6)

0.52

− 1.5 (− 6.3 to 3.6)

0.57

− 0.2 (− 7.3 to 7.4)

0.95

Absolute change

      

 TPV (mm3)

− 7.5 (− 18.9 to 4.0)

0.20

0.5 (− 10.6 to 11.6)

0.93

− 8.0 (− 24.0 to 8.0)

0.33

 Stenosis (%)

1.6 (− 0.2 to 3.4)

0.07

− 1.1 (− 2.8 to 0.7)

0.22

2.7 (0.2 to 5.2)

0.03*

 CIMT (mm)

0.0 (− 0.0 to 0.0)

0.58

0.0 (− 0.0 to 0.0)

0.43

− 0.0 (− 0.0 to 0.0)

0.88

 MPH (mm)

0.0 (− 0.1 to 0.1)

0.79

0.1 (0.0 to 0.3)

0.046*

− 0.1 (− 0.3 to 0.1)

0.23

 TPA (mm2)

− 0.7 (− 3.3 to 1.9)

0.60

− 0.3 (− 2.8 to 2.3)

0.83

− 0.4 (− 4.1 to 3.3)

0.82

  1. Statistical test: analysis of covariance controlling for site and baseline
  2. CIMT, carotid intima-media thickness; L-C, L-carnitine; MPH, maximum plaque height; TPA, total plaque area; TPV, total plaque volume
  3. *Significant